Health and Healthcare

Celgene : CELG

All CELG Articles

433 Articles

Chris Lange | Feb 28, 2018 at 9:15 AM EST

Major Biotechs Continue to See a Rising Tide of Short Interest

The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech…

Jon C. Ogg | Feb 28, 2018 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Celgene, Chevron, Exxon, Frontier Communications, JPMorgan, Lam Research, P&G, Square, Workday and More

The top analyst upgrades, downgrades and other research calls from Wednesday include Celgene, Chevron, Exxon Mobil, Frontier Communications, JPMorgan, Lam…

Trey Thoelcke | Feb 23, 2018 at 10:20 AM EST

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will…

Jon C. Ogg | Feb 17, 2018 at 9:40 AM EST

13 Fresh Dividend Hikes and Stock Buybacks Too Big to Ignore

These were 13 stock buyback and dividend hike announcements from the week of February 16 that were simply too large…

Lee Jackson | Feb 14, 2018 at 8:10 AM EST

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time…

Jon C. Ogg | Feb 13, 2018 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: ADT, CBOE, Celgene, JPMorgan, 3M, NetApp, Total, Tyson Foods, Weatherford and More

The the top analyst upgrades, downgrades and other research calls from Tuesday include ADT, CBOE, Celgene, JPMorgan, 3M, NetApp, Total,…

Chris Lange | Feb 12, 2018 at 9:15 AM EST

Major Biotechs See Rising Tide of Short Interest

The January 31 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Feb 3, 2018 at 8:50 AM EST

Major Biopharma Catalysts on February’s FDA Calendar

24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food…

Chris Lange | Jan 25, 2018 at 10:05 AM EST

Short Sellers Raise the Stakes in Major Biotechs

The January 12 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | Jan 22, 2018 at 10:10 AM EST

Why Celgene Is Betting Big on 2020 With Juno Acquisition

Juno Therapeutics saw its shares take off early on Monday after it was announced that Celgene would be acquiring it.

Chris Lange | Jan 17, 2018 at 10:15 AM EST

Why Juno Therapeutics Is Soaring

Juno Therapeutics saw its shares skyrocket early on Wednesday after reports that Celgene was in talks to acquire the company.

Chris Lange | Jan 11, 2018 at 9:50 AM EST

Short Sellers Grow More Selective on Major Biotechs

The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech…

Chris Lange | Jan 5, 2018 at 11:15 AM EST

Meet Merrill Lynch’s Top Biotech Picks for 2018

Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and…

Chris Lange | Dec 30, 2017 at 8:55 AM EST

30 Big Biotech Events Coming in 2018

Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock…

Chris Lange | Dec 28, 2017 at 11:50 AM EST

Top 10 Biopharma Events Kicking Off 2018

Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two…

1 … 4 5 6 7 8 … 29

Celgene : CELG

All CELG Articles

Major Biotechs Continue to See a Rising Tide of Short Interest

Top Analyst Upgrades and Downgrades: Celgene, Chevron, Exxon, Frontier Communications, JPMorgan, Lam Research, P&G, Square, Workday and More

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

13 Fresh Dividend Hikes and Stock Buybacks Too Big to Ignore

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

Top Analyst Upgrades and Downgrades: ADT, CBOE, Celgene, JPMorgan, 3M, NetApp, Total, Tyson Foods, Weatherford and More

Major Biotechs See Rising Tide of Short Interest

Major Biopharma Catalysts on February’s FDA Calendar

Short Sellers Raise the Stakes in Major Biotechs

Why Celgene Is Betting Big on 2020 With Juno Acquisition

Why Juno Therapeutics Is Soaring

Short Sellers Grow More Selective on Major Biotechs

Meet Merrill Lynch’s Top Biotech Picks for 2018

30 Big Biotech Events Coming in 2018

Top 10 Biopharma Events Kicking Off 2018

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Celgene : CELG

All CELG Articles

Major Biotechs Continue to See a Rising Tide of Short Interest

Top Analyst Upgrades and Downgrades: Celgene, Chevron, Exxon, Frontier Communications, JPMorgan, Lam Research, P&G, Square, Workday and More

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

13 Fresh Dividend Hikes and Stock Buybacks Too Big to Ignore

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

Top Analyst Upgrades and Downgrades: ADT, CBOE, Celgene, JPMorgan, 3M, NetApp, Total, Tyson Foods, Weatherford and More

Major Biotechs See Rising Tide of Short Interest

Major Biopharma Catalysts on February’s FDA Calendar

Short Sellers Raise the Stakes in Major Biotechs

Why Celgene Is Betting Big on 2020 With Juno Acquisition

Why Juno Therapeutics Is Soaring

Short Sellers Grow More Selective on Major Biotechs

Meet Merrill Lynch’s Top Biotech Picks for 2018

30 Big Biotech Events Coming in 2018

Top 10 Biopharma Events Kicking Off 2018

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%